
|Articles|February 1, 2004
- Pharmaceutical Executive-02-01-2004
Upping the Ante
With overworked execs and underfunded campaigns, it is hard to believe that the ad industry has the resources to improve its creativity while churning out campaigns better, faster, and cheaper. But this year?s Rx Club Awards winners show that a more sophisticated and risqué style is emerging?direct in message, clear on benefit, and confident in execution.
Advertisement
Articles in this issue
over 22 years ago
February Table of Contentsover 22 years ago
Knowing When to Pull the Plug On Your Experimental DrugAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5



